ERBB2 and breast carcinoma: Unlike estrogen receptor, progesterone receptor, or human epidermal growth factor receptor 2 positive breast cancers, TNBCs cannot be treated with endocrine therapies or HER2-targeted agents (Trastuzumab, Pertuzumab), and chemotherapies are standard of care.